Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05664126 · ClinicalTrials.gov registry record · Phase 2
Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation
A Phase 2 study of Adenovirus and Cytomegalovirus, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05664126 is a Phase 2 study of Adenovirus and Cytomegalovirus that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 42 participants, above the 24-participant average among 6 other Adenovirus trials with a reported enrollment target (75% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05664126, a Phase 2 study of Adenovirus and Cytomegalovirus, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators want to learn if CMV- and ADV-specific T-cells (cells that fight infections) isolated (selected) from a donor using an automated medical device can be a safe treatment for treating patients with CMV, and ADV after transplant.This study will test the effects and safety of giving VSTs produced here at St. Jude in treating the participant's infection. Primary objective To determine the efficacy of VSTs to achieve a ≥1 log10 reduction in CMV and/or ADV viral load in the peripheral blood 4 weeks after VST infusion. When the initial viral load is \<1 log10 above the threshold of detection, the objective is to achieve a reduction to below the threshold of detection. Secondary objectives * Determine the safety of VSTs when used to treat CMV and/or ADV viremia post-HCT. * Determine the proportion of patients who achieve a negative viral load at 3 months post-infusion. * Assess the persistence of response for 6 months post-infusion.
Conditions Studied
Interventions
- DRUG VST infusion
- DEVICE CliniMACS
Study Locations (1)
Tennessee
- St . Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05664126
The ClinicalTrials.gov registry entry for NCT05664126 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 24-participant average among 6 other Adenovirus trials with a reported enrollment target (75% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Adenovirus appearing as the primary indexed condition, and to 2 interventions - of which VST infusion is the first listed.
NCT05664126 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05664126 about?
NCT05664126 is a clinical study titled "Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation". The investigators want to learn if CMV- and ADV-specific T-cells (cells that fight infections) isolated (selected) from a donor using an automated medical device can be a safe treatment for treating patients with CMV, and ADV after transplant.This study will test the effects and safety of giving VST...
What is the current status of trial NCT05664126?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2023-08-01. Estimated completion is 2029-12-31.
What conditions does trial NCT05664126 study?
This clinical trial studies the following conditions: Adenovirus, Cytomegalovirus.
What interventions are being tested in trial NCT05664126?
The interventions under investigation include: VST infusion (DRUG), CliniMACS (DEVICE).
Who is sponsoring clinical trial NCT05664126?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05664126 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenovirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
RECRUITING · Phase 2
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
RECRUITING · Early Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.